Skip to main content

KILL Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials

 

Aditxt, Inc. requests that their press release NewsItemId: 20250414955183 issued April 14, 2025 “Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials” be killed.

The release was issued in error by Aditxt, Inc.

A replacement release will not be issued at this time.

Contacts

Aditxt, Inc. 

Corporate Communications 

Jeff Ramson, PCG Advisory, Inc. 

T: 646-863-6893 

contactus@aditxt.com

Recent Quotes

View More
Symbol Price Change (%)
AMZN  204.86
+0.07 (0.03%)
AAPL  260.58
-3.77 (-1.43%)
AMD  203.37
+3.25 (1.62%)
BAC  52.77
-0.59 (-1.11%)
GOOG  303.56
-0.38 (-0.13%)
META  644.78
+1.56 (0.24%)
MSFT  398.46
-1.14 (-0.29%)
NVDA  187.90
-0.08 (-0.04%)
ORCL  156.54
+0.37 (0.24%)
TSLA  411.71
+0.39 (0.09%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.